Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023

Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023

Abstract Introduction Baricitinib is an oral selective Janus kinase 1/2 inhibitor approved for the treatment of the immune-mediated inflammatory skin diseases atopic dermatitis (AD) and alopecia areata (AA). We report the findings of a systematic literature review of real-world outcomes with baricit...

Full description

Saved in:
Bibliographic Details
Main Authors: Julien Seneschal, lgnasi Figueras Nart, Silvia Sabatino, Manny Papadimitropoulos, Srishti Dabral, Anastasia Lampropoulou
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-05-01
Series:Dermatology and Therapy
Subjects:
Atopic dermatitis
Alopecia areata
Baricitinib
Real-world
Online Access:https://doi.org/10.1007/s13555-025-01425-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01425-y

Similar Items